Most neutralizing antibodies act at the earliest steps of viral infection and block interaction of the virus with cellular receptors to prevent entry into host cells. The inability to induce neutralizing antibodies to HIV has been a major obstacle to HIV vaccine research since the early days of the epidemic. However, in the past three years, the definition of a neutralizing antibody against HIV...

Neutralizing humoral immunity has been the subject of intense investigation since early human immunodeficiency virus (HIV) research. Although virtually all HIV-positive patients have antibodies capable of binding to HIV envelope protein, only a subset of these antibodies, termed neutralizing antibodies, are able to block viral entry into target cells. Neutralizing antibodies develop later than ...

Broadly neutralizing antibodies against rapidly evolving viruses (e.g., HIV-1 and influenza virus), often manifest antigen-binding promiscuity. Based on a recent study, we hypothesize the significance of antibody polyreactivity in neutralization viruses. We propose that contributes to toleration viral variants shortens time for generating antibodies.

We used 18 monoclonal antibodies against B19 parvovirus to identify neutralizing epitopes on the viral capsid. Of the 18 antibodies, 9 had in vitro neutralizing activity in a bone marrow colony culture assay. The overlapping polypeptide fragments spanning the B19 structural proteins were produced in a pMAL-c Escherichia coli expression system and used to investigate the binding sites of the neu...

Neutralizing antibodies against fowl tumor agents can be produced in rabbits by injection of heavy materials obtained from chicken tumor. Similar sediments from normal chicken spleen produce no neutralizing antibodies. The complement-fixing antibodies produced by both materials are unrelated to the neutralizing antibodies.

INTRODUCTION Antibodies to intravenous idursulfase enzyme replacement therapy (ERT) for patients with Hunter syndrome (mucopolysaccharidosis type II, MPS II) can have a harmful clinical impact, including both increasing risk of infusion reactions and inhibiting therapeutic activity. Thus, failure to monitor anti-idursulfase antibodies and neutralizing antibodies, and delays in reporting results...

See online version for legend and references.

Dengue viruses (DENVs) are mosquito-borne flaviviruses and the causative agents of dengue fever and dengue hemorrhagic fever. As there are four serotypes of DENV (DENV1-4), people can be infected multiple times, each time with a new serotype. Primary infections stimulate antibodies that mainly neutralize the serotype of infection (type-specific), whereas secondary infections stimulate responses...